Karisa Schreck is co-director of the BRAF Brain Tumor Center at Johns Hopkins. Her research focuses on the development of small-molecule targeted therapies for patients with primary brain tumors. Dr. Schreck has specific expertise in the treatment of BRAF gene mutations. As such, she works with Christine Pratilas’ laboratory to investigate resistance mechanisms to BRAF-targeted therapy. Dr. Schreck also writes and runs clinical trials for novel targeted agents through the Comprehensive Brain Tumor Center and the Alliance for Clinical Trials in Oncology. Dr. Schreck is rated as an Experienced provider by MediFind in the treatment of Pineoblastoma. Her top areas of expertise are Glioma, Brain Tumor, Astrocytoma, and Glioblastoma.

Dr. Jon Weingart focuses on the surgical treatment of brain tumors including benign and malignant tumors. Dr. Weingart also specializes in spinal disorders, such as cervical and lumbar disc disease, as well as other congenital and developmental abnormalities such as tethered spinal cord, spina bifida and chiari malformation. Dr. Weingart is rated as an Experienced provider by MediFind in the treatment of Pineoblastoma. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Awake Craniotomy, and Osteotomy.

Alan R. Cohen is the director of pediatric neurosurgery at Johns Hopkins Children’s Center in Baltimore, Maryland, and one of the top pediatric neurosurgeons in the country. His area of specialty is treating infants and children diagnosed with brain tumors. Dr. Cohen’s goal is to get his patients back to being a kid again. He has a patient-centered approach to caring for each of his patients, working closely with the child’s family at every stage of the decision-making process. Dr. Cohen sees patients in the neurosciences clinic located in the Levi Watkins, Jr., M.D., Outpatient Center. As the Carson-Spiro Professor of Pediatric Neurosurgery, Dr. Cohen is a leader in developing minimally invasive techniques to enhance the safety and efficacy of selected pediatric neurosurgical procedures. He serves as director of the Minimally Invasive Neurosurgery Laboratory at Johns Hopkins and directs the Minimally Invasive Neurosurgery Fellowship Program. His lab focuses on developing novel instruments and surgical approaches. He has authored more than 200 peer-reviewed journal articles and book chapters, and published two textbooks. He has given approximately 330 national and international presentations, and has been an invited visiting professor at 50 medical centers. He is past president of the Society of Neurological Surgeons, the American Society of Pediatric Neurosurgeons and the AANS/CNS Section on Pediatric Neurological Surgery. He is past vice president of the American Academy of Neurological Surgery, a past director of the American Board of Neurological Surgery and current director of the American Board of Pediatric Neurological Surgery. Patient Reviews Hear what patients have to say about Dr. Cohen’s care: • Healthgrades Patient Reviews • Vitals Patient Reviews. Dr. Cohen is rated as an Experienced provider by MediFind in the treatment of Pineoblastoma. His top areas of expertise are Arachnoid Cysts, Meningocele, Hydrocephalus, Endoscopy, and Cerebral Artery Bypass Surgery.

Bardia Nourbakhsh, M.D., M.A.S., is an associate professor of neurology at Johns Hopkins University School of Medicine. He practices out of The Johns Hopkins Hospital in Baltimore, Maryland. Dr. Nourbakhsh has expertise in multiple sclerosis (MS) and neuroimmunology. Dr. Nourbakhsh earned his medical degree from the Tehran University School of Medical Sciences and completed a residency in neurology at the University of Texas Southwestern Medical Center. He studied epidemiology, study design, and biostatistics, obtaining a Master of Advanced Studies degree in clinical research from the University of California, San Francisco School of Medicine, where he also completed a fellowship in MS and neuroimmunology. In 2014, Dr. Nourbakhsh earned the American Brain Foundation Clinical Research Training Fellowship in MS, the National Multiple Sclerosis Society Sylvia Lawry Clinical Research Fellowship, the Fred Baskin Young Investigator Award, and the Teva Neuroscience Award for Academic Excellence. In 2022, he was named a Harry Weaver Neuroscience Scholar by the National Multiple Sclerosis Society. Dr. Nourbakhsh's research training focused on the design and execution of clinical trials and the use of biomarkers in MS. His current research interests include the comparative effectiveness studies of symptomatic and disease-modifying therapies in MS, as well as identifying new pathophysiologic mechanisms and therapeutic targets for MS-related fatigue. Dr. Nourbakhsh is the principal investigator of a randomized, double-blind clinical trial funded by the Department of Defense, which tests whether ketamine could be a treatment for MS fatigue. He has contributed to numerous publications, journal articles, abstracts and posters, and lectures. He is an ad hoc reviewer for Lancet Neurology, Annals of Neurology, Neurology, Neurology: Neuroimmunology and Neuroinflammation, Multiple Sclerosis Journal, and other journals. Dr. Nourbakhsh is rated as an Experienced provider by MediFind in the treatment of Pineoblastoma. His top areas of expertise are Multiple Sclerosis (MS), Relapsing Multiple Sclerosis (RMS), Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, and Meningocele.

Dr. Matthias Holdhoff is a medical oncologist and co-director of the Brain Cancer Disease Group at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is a professor of oncology, neurology and neurological surgery at Johns Hopkins University School of Medicine. Dr. Holdhoff’s expertise is in primary brain cancers and central nervous system lymphomas. He earned his medical degree from Freie Universität Berlin, received his doctorate degree at Charité University Medicine Berlin. Dr. Holdhoff completed residency training in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training at the Ludwig Center for Cancer Genetics and Therapeutics (Kinzler-Vogelstein lab). As a clinical investigator in neuro-oncology, his research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He has led and contributed to numerous clinical trials, publications and presentations. Dr. Holdhoff serves as the director of the solid tumor inpatient service at the Sidney Kimmel Comprehensive Cancer Center. He is passionately involved in mentoring and teaching of fellows, residents and students. He is the director of the UCNS-certified neuro-oncology fellowship program at Johns Hopkins, and he is a teaching attending physician for the Osler internal medicine residency program. Dr. Holdhoff is rated as an Experienced provider by MediFind in the treatment of Pineoblastoma. His top areas of expertise are Glioma, Glioblastoma, Astrocytoma, and Brain Tumor.

Dr. Jaishri Blakeley is the Marjorie Bloomberg Tiven Professor of Neurofibromatosis in Neurology, Oncology, and Neurosurgery at Johns Hopkins School of Medicine, director of the Johns Hopkins Comprehensive Neurofibromatosis Center and director of the Neurofibromatosis Therapeutic Acceleration Program (NTAP). She is an active clinician-scientist specializing in the care of people with NF1, NF2, LZTR1, SMARC1 schwannomatoses, and primary brain tumors. Her research expertise in the development of clinical trials for nervous system tumors and specifically, early clinical-translational studies including tumor pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumors, and incorporation of patient-focused, functional endpoints into efficacy studies. She has been the national or international leader of 7 clinical trials focused on therapies for glioblastoma, NF1 and NF2. In 2012 she cofounded the NTAP to dramatically shift the landscape of NF1 via necessary, efficient, and expert discovery, translational and clinical research. NTAP focuses on therapeutics, fosters collaboration, facilitates open and timely sharing of results, and streamlines the research process to accelerate therapies for plexiform and cutaneous neurofibromas. Through NTAP, Dr. Blakeley has supported and collaborated with more than 80 laboratories and research teams across the globe enabling meaningful therapeutic development for NF1-associated neoplasms and supporting the development of an exceptional community of clinician scientists focused on NF1 via the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research. Her research and programmatic efforts are all in the service of improving outcomes for the patients with NF1, NF2, schwannomatosis, and primary brain cancer for whom she is honored to provide care. Dr. Blakeley is rated as an Experienced provider by MediFind in the treatment of Pineoblastoma. Her top areas of expertise are Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis Type 1 (NF1), and Laminectomy.

Haroon Ahmad is a Neurologist in Baltimore, Maryland. Dr. Ahmad is rated as an Experienced provider by MediFind in the treatment of Pineoblastoma. His top areas of expertise are Oligodendroglioma, Glioma, Astrocytoma, and Glioblastoma.

Jignesh Tailor is a General Surgeon and a Neurosurgery provider in Baltimore, Maryland. Dr. Tailor is rated as an Experienced provider by MediFind in the treatment of Pineoblastoma. His top areas of expertise are Choroid Plexus Cyst, Hydrocephalus, Hydrocephalus due to Congenital Stenosis of Aqueduct of Sylvius, Rhizotomy, and Awake Craniotomy.

Sama Ahsan is a Pediatric Hematologist Oncology provider in Baltimore, Maryland. Dr. Ahsan is rated as an Experienced provider by MediFind in the treatment of Pineoblastoma. Her top areas of expertise are Diffuse Midline Glioma H3 K27M-Mutant, Embryonal Tumor with Multilayered Rosettes, Pineoblastoma, and Glioma.

Dr. Debraj “Raj” Mukherjee’s clinical focus is the treatment of patients with primary and metastatic brain lesions. His clinical work and research emphasize the development of individual treatment plans that optimize survival and quality of life in all patients. After receiving his medical degree from Dartmouth Medical School, Dr. Mukherjee was recruited to Johns Hopkins, where he studied epidemiology, biostatistics and clinical design at the Johns Hopkins Bloomberg School of Public Health and served as Director of the Neuro-Oncology Surgical Outcomes Laboratory in the Department of Neurosurgery. Dr. Mukherjee completed neurosurgery residency at Cedars-Sinai Medical Center, where he was named a Robert Wood Johnson Foundation Health & Society Scholar. He completed an open and endoscopic skull base fellowship with the Center for Skull Base Surgery at University of Pittsburgh Medical Center, where he was a Copeland Scholar. Throughout his career, Dr. Mukherjee has led patient-centered research pursuits in neuro-oncology including development of a national registry for patients with brain tumors, creation of disease-specific quality of life instruments for patients with skull base tumors, and development of innovative clinical trials in neuro-oncology. He leads the Meningioma, Brain Metastasis, and Neurosurgical Oncology centers at Johns Hopkins Medicine, and he serves as Assistant Residency Program Director for one of the largest neurosurgical training programs in the country. His work has been supported by the American Medical Association, Glioblastoma Foundation, National Institute on Aging, and National Cancer Institute. Dr. Mukherjee can be contacted at drraj@jhmi.edu. Dr. Mukherjee is rated as an Experienced provider by MediFind in the treatment of Pineoblastoma. His top areas of expertise are Meningioma, Pituitary Tumor, Brain Tumor, Awake Craniotomy, and Laminectomy.